Investors/Media

Adelene Q. Perkins has served as Infinity's president and chief executive officer since 2009 and as board chair since 2012. Ms. Perkins first joined Infinity as chief business officer in 2002 and was named president in 2008. She has played an integral role in building the company, leading its transition from a platform to a product-based organization. She was the principal figure in structuring and restructuring Infinity's strategic relationships which have played a critical role in developing the company’s current product portfolio. Ms. Perkins has more than 25 years of international business experience in the biopharmaceutical industry, focused on building and leading high-caliber, cross-functional teams, corporate strategy, licensing and business development, strategic finance, and product life cycle management.

Ms. Perkins joined Infinity from TransForm Pharmaceuticals where she was an early member of the management team that built the company prior to its acquisition by J&J. Prior to TransForm, she was vice president of emerging businesses and the cofounder and general manager of the DiscoverEaseT business unit at Genetics Institute, now part of Pfizer. She also formed and served as chief executive officer of MetaMorphix, a joint venture between Genetics Institute and Johns Hopkins University. She joined GI from Bain & Company where she spent seven years providing strategic and operational advice to clients in the healthcare industry.

Ms. Perkins received her M.B.A. from Harvard Business School and her B.S. in chemical engineering from Villanova University. She is vice chair of the board of Project Hope and a member of the Villanova University College of Engineering Advisory Board.